Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours, non-colorectal 2

3681 - Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma


09 Oct 2016


Gastrointestinal tumours, non-colorectal 2


Martin Schuler


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


M. Schuler1, S. Al-Batran2, Z. Zvirbule3, G. Manikhas4, F. Lordick5, A. Rusyn6, Y. Vinnyk7, I. Vynnychenko8, N. Fadeeva9, M. Nechaeva10, A. Dudov11, E. Gotovkin12, A. Pecheniy13, I. Bazin14, I. Bondarenko15, B. Melichar16, C. Huber17, Ö. Türeci18, U. Sahin17

Author affiliations

  • 1 Medical Oncology, University Hospital Essen Westdeutsches Tumorzentrum, 45147 - Essen/DE
  • 2 Medical Oncology, Institute of Clinical Cancer Research (IKF), UCT-University Cancer Center,, Frankfurt/DE
  • 3 Department Of Oncology, Oncology Center of Latvia Riga East University Hospital, Riga/LV
  • 4 Department Of Gynaecological Oncology, City Clinical Oncology Center, St-Petersburg/RU
  • 5 University Cancer Center Leipzig, University Clinic Leipzig, 04103 - Leipzig/DE
  • 6 Department Of Chemotherapy, Zakarpattya Regional Clinical Oncological Center, 88014 - Uzhhorod/UA
  • 7 Oncology, CHI Kharkiv Regional Clinical Oncological Center, Kharkiv/UA
  • 8 Oncology, Sumy Regional Oncology Center, 40005 - Sumy/UA
  • 9 Chemotherapy Dept., Chelyabinsk Regional Clinical Oncology Center, Chelyabinsk/RU
  • 10 Chemotherapy Dept., Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk/RU
  • 11 Medical Oncology Dpt., University Hospital Queen Giovanna UMHAT Tsaritsa Yoanna- ISUL, 1527 - Sofia/BG
  • 12 Chemotherapy Dept., Ivanovo Regional Oncology Center, Ivanovo/RU
  • 13 Oncology Dept., Orel Oncology Center, Orel/RU
  • 14 Clinical Pharmacology And Chemotherapy, N. N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU
  • 15 Department Of Oncology, Radiodiagnosis And Radiotherapy, Dnipropetrovsk Municipal Clinical Hospital #4, 49102 - Dnepropetrovsk/UA
  • 16 Clinic Of Oncology, University Hospital Olomouc, 77520 - Olomouc/CZ
  • 17 Tron-translational Oncology At The University Medical Center Of The Johannes Gutenberg University Mainz, University Medical Center of the Johannes Gutenberg University, Mainz/DE
  • 18 N/a, Ganymed Pharmaceuticals AG, Mainz/DE


Abstract 3681


IMAB362, a chimeric monoclonal antibody that mediates specific killing of cancer cells expressing the tight junction protein Claudin18.2 (CLDN18.2) by activation of immune effector mechanisms, has demonstrated single-agent activity and tolerability in patients (pts) with heavily pretreated gastric cancer.


Pts with advanced/recurrent gastric and GEJ cancer were centrally evaluated for CLDN18.2 expression by immunohistochemistry (CLAUDETECT® 18.2 Histology Kit). Eligible pts had a CLDN18.2 expression of ≥2+ in ≥40% tumor cells, an ECOG PS of 0–1 and were not eligible for trastuzumab. Pts were randomized 1:1 to first-line EOX (epirubicin 50 mg/m2 and oxaliplatin 130 mg/m2 d1, and capecitabine 625 mg/m2 bid, d1–21; qd22) with or without IMAB362 (loading dose 800 mg/m2, then 600 mg/m2 d1, qd21). An exploratory arm (N = 85) was added to investigate a higher dose IMAB362 (1000 mg/m2) plus EOX. The primary study endpoint was PFS (Arm1 vs 2, 70% power, hazard ratio [HR] 0.72, 1-sided p = 0.1). Here we present the final study results.


Of 686 biomarker-assessable pts, 334 pts (48%) were tested CLDN18.2+ per protocol criteria. Of those, 161 pts (median age 58 years; 80% gastric, 16% GEJ, 4% esophageal; 44% diffuse, 33% intestinal) were randomized into Arms 1 and 2. IMAB362 plus EOX improved PFS (median 4.8 vs 7.9 months; HR 0.47; 95% confidence interval [CI] 0.31–0.70, 1-sided p = 0.0001), OS (median 8.4 vs 13.2 months; HR 0.51, 95% CI 0.36–0.73, p = 0.0001) and ORR (28% vs 43%) compared to EOX. Common IMAB362-related adverse events included vomiting, neutropenia, and anemia, which were mostly of NCI-CTCAE grade 1 or 2. Grade 3/4 events were not significantly increased by IMAB362.


This final analysis confirms that addition of IMAB362 to first-line chemotherapy provides a clinically relevant benefit in patients with inoperable or recurrent gastric and GEJ cancer.

Clinical trial identification

ClinicalTrials.gov NCT01630083

Legal entity responsible for the study

Ganymed Pharmaceuticals AG


Ganymed Pharmaceuticals AG


M. Schuler: Corporate-sponsored research: BI, BMS, Novartis. Honoraria/Consultancy: Alexion, AstraZeneca, BI, BMC, Celgene, IQWig, GSK, Lilly, Novartis, Pfizer. Patents and employment: University Duisburg-Essen. S.–E. Al-Batran: Advisory role: Merck, Roche, Celgene, Lilly, Nordic Pharma. Speaker: Roche, Celgene, Lilly, Nordic Pharma. Research grants: Merck, Roche, Celgene, Vifor, Medac, Hospira, Lilly. F. Lordick: Research support: GSK, Fresenius Biotech. Lecture and Advisory honoraria: Amgen, Biontech, BMS, Eli Lilly, Ganymed, Merck-Serono, Merck-MSD, Nordic, Roche. Travel support: Amgen, Bayer, Roche, Taiho. C. Huber: Stock owner of Ganymed and of BioNTech shares. Member of Ganymed's and of BioNTech's supervisory board. Scientific Advisor of Ganymed, of BioNTech and of TRON. Executive board member of CI3-Cluster. Ö. Türeci: Stock ownership: Ganymed Pharmaceuticals AG. Advisory board: Ganymed Pharmaceuticals AG. Patents: Ganymed Pharmaceuticals AG, BioNTech Holding. Employment, leadership role: Ganymed Pharmaceuticals AG. U. Sahin: Stock ownership: BioNTech Holding Advisory Board: Ganymed Pharmaceuticals AG. Patents: Ganymed Pharmaceuticals AG, BioNTech Holding. Employment, leadership role: BioNTech Holding. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings